Introduction
Clinical management of cardiovascular disease has long been anchored by the identification and control of "Standard Modifiable cardiovascular Risk Factors" (SMuRFs): hypertension, hypercholesterolemia, diabetes mellitus, and smoking. These factors are the cornerstones of risk stratification and primary prevention. However, a growing clinical phenomenon involves patients presenting with Acute Coronary Syndrome (ACS) who possess none of these traditional markers.
Recent studies in Western populations have suggested a "SMuRF-less paradox," where patients without these risk factors experience worse clinical outcomes than those with them. This study aims to determine if this paradox persists in a multi-ethnic Asian population, a demographic with distinct genetic profiles and lifestyle patterns that may influence cardiovascular pathology differently.
Methodology
This study utilized a large-scale clinical dataset from a major tertiary "hub-and-spoke" hospital network in Singapore. Researchers conducted a retrospective cohort analysis of 8,680 consecutive patients admitted for ACS between January 1, 2011, and March 31, 2021.
The cohort was multi-ethnic, reflecting Singapore's population: Chinese (61%), Malay (21.2%), and Indian (17.1%). Patients were classified as "SMuRF-less" if they had no history of hypertension, hypercholesterolemia, or diabetes, and were non-smokers. The primary endpoint was 30-day cardiovascular mortality. Secondary endpoints included all-cause mortality, readmission rates, cardiogenic shock, stroke, and heart failure. To ensure robust results, the team employed multivariable regression analysis, adjusting for age, sex, ethnicity, chronic kidney disease, ACS type (STEMI vs. NSTEMI), and the presence of high-risk coronary lesions.
Results and Survival Analysis
Of the total population studied, 746 patients (8.6%) were identified as SMuRF-less. Demographically, these patients were significantly younger (mean age 57 vs. 61 years) and had a lower prevalence of pre-existing comorbidities such as stroke and chronic kidney disease compared to the SMuRF group.
Despite their seemingly "healthier" profile, SMuRF-less patients presented with higher clinical severity. They exhibited significantly higher rates of ventricular arrhythmias and required more intensive interventions, including inotropic support and invasive mechanical ventilation.
The multivariable analysis confirmed that SMuRF-less status was an independent predictor of poor outcomes. These patients faced a 48% higher risk of cardiovascular mortality (HR 1.48, 95% CI 1.09–1.86, p=0.048). Furthermore, they were at significantly higher risk for cardiogenic shock (RR 1.31, 95% CI 1.09–1.52) and stroke (RR 2.51, 95% CI 1.67–3.34).
Survival analysis using Kaplan-Meier curves demonstrated that the divergence in cardiovascular mortality occurs very early—often within the first few days of admission.
Discussion
The findings reveal a critical gap in current cardiovascular risk assessment. The "SMuRF-less paradox" in this Asian cohort highlights that the absence of traditional risk factors can lead to a deceptive sense of security for both patients and clinicians.
One potential driver for the worse outcomes is the "treatment gap." The study found that SMuRF-less patients were less likely to be prescribed guideline-directed medical therapies (GDMT) upon discharge, including statins, beta-blockers, and ACE-inhibitors/ARBs. This suggests that clinicians may perceive these patients as lower risk, leading to less aggressive secondary prevention.
The consistency of these results across Chinese, Malay, and Indian ethnicities suggests a biological or systemic driver that transcends specific ethnic backgrounds. The increased risk was particularly notable in men and those presenting with ST-segment elevation myocardial infarction (STEMI), the most acute form of heart attack.
Limitations and Future Directions
While this study provides strong evidence of increased risk in SMuRF-less patients, it is limited by its retrospective, single-center design. Additionally, the study focused on short-term (30-day) outcomes; long-term longitudinal data is necessary to understand if this risk profile persists over time.
Future research should investigate non-traditional risk factors that may be prevalent in this subgroup, such as elevated Lipoprotein(a), genetic predispositions, environmental stressors, or specific protein deficiencies. Identifying these "hidden" drivers is essential for developing targeted screening and treatment protocols.
Conclusion
In conclusion, ACS patients without standard modifiable risk factors represent an unexpectedly high-risk subgroup in the Asian population. Despite their younger age and fewer comorbidities, they suffer from higher mortality and complication rates. There is an urgent need for clinicians to recognize this paradox and ensure that SMuRF-less patients receive the same intensive monitoring and guideline-directed therapy as their counterparts with traditional risk factors.
Summary updated